Earlier this month, the Chinese disease control authorities began funding of a new vaccine trial, a mix of CanSino Biologics' Ad5-nCoV vaccine and Chongqing Zhifei Biological Products' ZF2001 vaccine. The Ad5-nCoV vaccine currently has an efficacy rate of 68.83% in "preventing symptomatic COVID-19 two weeks after injection" according to a report from Reuters.
CanSino Biologics' co-founder Xuefeng Yu says a Covid-19 an inhalable version of the Ad5-nCoV vaccine is also being developed. The company had already been working on an inhaled tuberculosis vaccine since 2013. CanSino Biologics hopes that using the same technology will lower the dosage required of the Ad5-nCoV vaccine without compensating efficacy.